Ulrike Potschger

St. Anna Kinderspital
Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Journal: Blood advances

Published: February 11, 2026

Disease Extent, Not Lesion Location, Determines Relapse Risk in Single-System Skeletal Langerhans Cell Histiocytosis.

Disease Extent, Not Lesion Location, Determines Relapse Risk in Single-System Skeletal Langerhans Cell Histiocytosis.

Journal: Blood advances

Published: February 11, 2026

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.

Journal: EJHaem

Published: January 13, 2026

Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.

Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.

Journal: Blood advances

Published: November 19, 2025

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.

Journal: Blood advances

Published: November 19, 2025

Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.

Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.

Journal: Blood

Published: July 23, 2025

Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.

Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.

Journal: Blood

Published: July 23, 2025

International neuroblastoma risk group consortium: a model of a networking for rare cancers.

International neuroblastoma risk group consortium: a model of a networking for rare cancers.

Journal: Journal of the National Cancer Institute

Published: June 22, 2025

International neuroblastoma risk group consortium: a model of networking for rare cancers.

International neuroblastoma risk group consortium: a model of networking for rare cancers.

Journal: Journal of the National Cancer Institute

Published: June 22, 2025

Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma - a multi-center study.

Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma - a multi-center study.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 29, 2025

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 17, 2025

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.

Journal: Blood advances

Published: August 19, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026